|Min SIP Amount||₹500|
|NAV||₹18.35 (17 Jun 2021)|
|Fund Started||10 Jul 2019|
|Fund Size||₹550 Cr|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||11.3%|
|Dr. Reddy's Laboratories Ltd.||Healthcare||Equity||10.0%|
|Divi's Laboratories Ltd.||Healthcare||Equity||8.3%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||6.3%|
|Apollo Hospitals Enterprise Ltd.||Healthcare||Equity||4.9%|
|Alkem Laboratories Ltd.||Healthcare||Equity||4.1%|
|Torrent Pharmaceuticals Ltd.||Healthcare||Equity||3.6%|
|Fortis Healthcare Ltd.||Healthcare||Equity||3.4%|
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth is a Equity Mutual Fund Scheme launched by Aditya Birla Sun Life Mutual Fund. This scheme was made available to investors on 10 Jul 2019. Dhaval Shah is the Current Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth fund.The fund currently has an Asset Under Management(AUM) of ₹550 Cr and the Latest NAV as of 17 Jun 2021 is ₹18.35.
The Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth is rated High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 1000. Exit load of 1% if redeemed within 30 days.
The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India.